
    
      1. Males or females aged 18 years or older who are undergoing either an autologous or
           allogeneic HSCT.

        2. The indications for HSCT may include, but not limited to the following diseases :

             1. Acute Leukemia, myeloid, lymphoid or biphenotypic in 1st, 2nd remission or in
                relapse

             2. Chronic Myeloid Leukemia in chronic, accelerated or blast phase

             3. Chronic Lymphocytic Leukemia

             4. Myelodysplastic Syndrome

             5. Myeloproliferative Disorder

             6. Lymphoma

             7. Myeloma

        3. All study patients must provide consent at least 1 day prior to scheduled HSCT and
           provide written informed consent.
    
  